The Prognostic Value of Long Non-Coding RNA SNHG7 in Human Cancer: A Meta-Analysis

Background: The long non-coding RNA SNHG7 is upregulated in many types of cancer and plays a role as an oncogene. However, its overall predictive ability in human cancer prognosis has not been assessed using existing databases. Therefore, further study of its prognostic value and clinical significance in human malignancies is warranted. Methods: We systematically collected relevant literature from multiple electronic document databases about the relationship between SNHG7 expression level and prognosis in patients with solid cancers. We further screened them for eligibility. Pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were used to assess the prognostic value. Odds ratios (ORs) and their 95% CIs were collected to evaluate the relationship between the expression of SNHG7 and clinicopathological features, including lymph node metastasis (LNM), tumour size, tumour node metastasis (TNM) stage and histological grade. Results: Fourteen original studies involving 971 patients were enrolled strictly following the inclusion and exclusion criteria. The meta-analysis showed that SNHG7 expression was significantly correlated with poor overall survival (HR = 1.93, 95% CI: 1.64–2.26, p<0.001) in human cancer patients. In addition, the pooled OR indicated that overexpression of SNHG7 was associated with earlier LNM (OR = 1.83, 95% CI: 1.44–2.32; P <0.001), and advanced TNM stage (OR = 1.82, 95% CI: 1.44–2.30; P <0.001).Meanwhile, there was no significant heterogeneity between the selected studies, proving the reliability of the meta-analysis results. Conclusions: High SNHG7 expression may predict poor oncological outcomes in patients with multiple human cancers, which could be a novel prognostic biomarker of unfulfilled clinicopathological features. However, further high-quality studies are needed to verify and strengthen the clinical value of SNHG7 in different types of cancer.

Download Full-text

The Prognostic Value of Long Non-Coding RNA SNHG7 in Human Cancer: A Meta-Analysis.

10.21203/rs.3.rs-139568/v1 ◽

2021 ◽

Author(s):

Kexun Yu ◽

Lu Chen ◽

Zihua Chen ◽

Weijie Yuan ◽

Pengwei Zeng ◽

...

Keyword(s):

Prognostic Value ◽

Human Cancer ◽

Meta Analysis ◽

Clinicopathological Features ◽

Tnm Stage ◽

Significant Heterogeneity ◽

Node Metastasis ◽

Non Coding Rna ◽

The Relationship ◽

Long Non Coding Rna

Abstract Background: The long non-coding RNA SNHG7 is upregulated in many types of cancer and plays a role as an oncogene. However, its overall predictive ability in human cancer prognosis has not been assessed using existing databases. Therefore, further study of its prognostic value and clinical significance in human malignancies is warranted.Methods: We systematically collected relevant literature from multiple electronic document databases about the relationship between SNHG7 expression level and prognosis in patients with solid cancers. We further screened them for eligibility. Pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were used to assess the prognostic value. Odds ratios (ORs) and their 95% CIs were collected to evaluate the relationship between the expression of SNHG7 and clinicopathological features, including lymph node metastasis (LNM), tumour size, tumour node metastasis (TNM) stage and histological grade.Results: Fourteen original studies involving 971 patients were enrolled strictly following the inclusion and exclusion criteria. The meta-analysis showed that SNHG7 expression was significantly correlated with poor overall survival (HR = 1.93, 95% CI: 1.64–2.26, p < 0.001) in human cancer patients. In addition, the pooled OR indicated that overexpression of SNHG7 was associated with earlier LNM (OR = 1.83, 95% CI: 1.44–2.32; P <0.001), and advanced TNM stage (OR = 1.82, 95% CI: 1.44–2.30; P <0.001).Meanwhile, there was no significant heterogeneity between the selected studies, proving the reliability of the meta-analysis results.Conclusions: High SNHG7 expression may predict poor oncological outcomes in patients with multiple human cancers, which could be a novel prognostic biomarker of unfulfilled clinicopathological features. However, further high-quality studies are needed to verify and strengthen the clinical value of SNHG7 in different types of cancer.

Download Full-text

The value of lncRNAs as prognostic biomarkers on clinical outcomes in osteosarcoma: a meta-analysis

BMC Cancer ◽

10.1186/s12885-021-07882-w ◽

2021 ◽

Vol 21 (1) ◽

Author(s):

Wenchao Zhang ◽

Xiaolei Ren ◽

Lin Qi ◽

Chenghao Zhang ◽

Chao Tu ◽

...

Keyword(s):

Web Of Science ◽

Meta Analysis ◽

Positive Outcome ◽

Clinical Applications ◽

Clinicopathological Features ◽

Cochrane Library ◽

Human Osteosarcoma ◽

Non Coding Rna ◽

The Cochrane Library ◽

Long Non Coding Rna

Abstract Background In recent years, emerging studies have demonstrated critical functions and potential clinical applications of long non-coding RNA (lncRNA) in osteosarcoma. To further validate the prognostic value of multiple lncRNAs, we have conducted this updated meta-analysis. Methods Literature retrieval was conducted by searching PubMed, Web of Science and the Cochrane Library (last update by October 2, 2019). A meta-analysis was performed to explore association between lncRNAs expression and overall survival (OS) of osteosarcoma patients. Relationships between lncRNAs expression and other clinicopathological features were also analyzed respectively. Results Overall, 4351 patients from 62 studies were included in this meta-analysis and 25 lncRNAs were identified. Pooled analyses showed that high expression of 14 lncRNAs connoted worse OS, while two lncRNAs were associated with positive outcome. Further, analysis toward osteosarcoma clinicopathologic features demonstrated that overexpression of TUG1 and XIST indicated poor clinical parameters of patients. Conclusions This meta-analysis has elucidated the prognostic potential of 16 lncRNAs in human osteosarcoma. Evidently, desperate expression and functional targets of these lncRNAs offer new approaches for prognosis and therapy of osteosarcoma.

Download Full-text

Association Between Long Non-Coding RNA POLR2E rs3787016 Polymorphism and Cancer Susceptibility: A Meta-analysis of 8725 Cancer Cases and 10710 Controls

Shiraz E-Medical Journal ◽

10.5812/semj.102065 ◽

2020 ◽

Vol In Press (In Press) ◽

Author(s):

Saeid Ghavami ◽

Mohsen Taheri ◽

Mohammad Hashemi

Keyword(s):

Breast Cancer ◽

Web Of Science ◽

Cancer Susceptibility ◽

Meta Analysis ◽

Positive Association ◽

Cancer Development ◽

Non Coding Rna ◽

Stratified Analysis ◽

The Relationship ◽

Long Non Coding Rna

Objectives: Several studies have reported a correlation between the POLR2E rs3787016 polymorphism and cancer development, but findings are inconsistent. Therefore, we designed the current study to understand how rs3787016 polymorphism impacts cancer susceptibility. Methods: We searched the Scopus, Web of Science, and PubMed databases for studies related to the topic of interest published up to March 2019. A total of 11 relevant studies, encompassing 8,761 cancer cases and 10,534 controls, were retrieved and subject to quantitative analysis. The strength of the relationship was evaluated using the pooled odds ratios (ORs) with 95% confidence intervals (CIs). Results: Overall, the findings proposed a positive association between rs189037 polymorphism and susceptibility to cancer in homozygous (OR = 1.32, 95% CI = 1.11 - 1.57, P = 0.002, TT vs. CC), recessive (OR = 1.21, 95% CI = 1.06-1.39, P = 0.005, TT vs. CT + CC), and allele (OR = 1.12, 95% CI = 1.02-1.22, P = 0.021, T vs. C) genetic models. Stratified analysis showed that rs3787016 increased the risk of prostate and breast cancer. In addition, we found a significant association between the variant and increased cancer risk in Asian and Caucasian populations. Conclusions: In summary, the findings of the current meta-analysis suggest that the POLR2E rs3787016 polymorphism is an indicator of cancer susceptibility.

Download Full-text

Long non-coding RNA FTX predicts a poor prognosis of human cancers: a meta-analysis

Bioscience Reports ◽

10.1042/bsr20203995 ◽

2021 ◽

Author(s):

Weiwei Chen ◽

Yuting Li ◽

Liliangzi Guo ◽

Chenxing Zhang ◽

Shaohui Tang

Keyword(s):

Meta Analysis ◽

Clinical Stage ◽

Predictive Marker ◽

Clinicopathological Characteristics ◽

Cochrane Library ◽

Hazard Ratios ◽

Non Coding Rna ◽

The Relationship ◽

Long Non Coding Rna

Background: Several studies have assessed the relationship between long non-coding RNA five prime to Xist (FTX) expression, clinicopathological features, and survival outcomes in cancer patients with conflicting results. This meta-analysis synthesized existing data to clarify the association between FTX with cancer prognosis.Methods: PubMed, Embase, Cochrane library, Web of Science, Chinese CNKI, and the Chinese WanFang databases were used to search for relevant studies. Role of FTX in cancers was evaluated by pooled odds ratios (ORs) and hazard ratios (HRs) with 95% confidence intervals (CIs).Results: Eleven studies comprising 1,210 participants including colorectal cancer (CRC), hepatocellular carcinoma (HCC), gastric cancer (GC), renal cell carcinoma (RCC), osteosarcoma (OSC), and glioma were enrolled in this analysis. The meta-analysis showed that high FTX expression was significantly associated with several clinicopathological characteristics, including lymph node metastasis in patients with CRC, GC, HCC, and RCC, distant metastasis in patients with CRC, GC, HCC, and OSC, larger tumor size in patients with CRC, GC, HCC, RCC, and OSC, and subsequently TNM/clinical stage in patients with CRC, GC, HCC, OSC, and glioma. The pooled results from the survival analysis revealed a significant correlation between high FTX expression and shorter OS in patients with HCC, CRC, GC, OSC, and glioma. Further, FTX overexpression could be an independent predictive marker for shorter OS in patients with CRC, HCC, OSC, and glioma. Conclusions: FTX may be a potential oncogene, with high FTX expression being associated with a poorer prognosis in patients with CRC, HCC, OSC, and glioma

Download Full-text

The prognostic value of long non-coding RNA PlncRNA-1 in patients with cancers: a systematic review and meta-analysis

10.21203/rs.3.rs-15903/v1 ◽

2020 ◽

Author(s):

Lijun Lei ◽

Lianbing Sheng ◽

Lingyuan Wu ◽

Jiaojing Liu ◽

Bin Wei ◽

...

Keyword(s):

Web Of Science ◽

Prognostic Biomarker ◽

Meta Analysis ◽

Database Search ◽

Clinical Prognosis ◽

Non Coding Rna ◽

Increased Risk ◽

Cancer Types ◽

The Relationship ◽

Long Non Coding Rna

Abstract Background We performed this meta-analysis to elucidate whether the expression of PlncRNA-1 might serve as an effective prognostic marker for various cancers. Methods We conducted a database search of PubMed, ScienceDirect, Embase, Web of Science and CNKI database (up to Oct 31, 2019). The pooled hazard ratio (HR), odds ratio (OR) and 95% confidence interval (CI) were used to estimate the strength of the relationship between PlncRNA-1 expression and the clinical prognosis of cancer patients. Results The results showed that elevated PlncRNA-1 expression predicted a poor OS with pooled HRs of 1.43 (95% CI: 1.25-1.63, I 2 =63.1%, P=0.004). Likewise, we found that advanced tumour stages were associated with upregulated PlncRNA-1 expression in various cancer types (III–IV vs I–II: OR=2.79, 95% CI: 1.76-4.41, I 2 =0%, P=0.822),patients with high PlncRNA-1 expression might have an increased risk of large tumours (OR=2.03, 95% CI: 1.31-3.14, I 2 =67.1%, P=0.028). Conclusions PlncRNA-1 might be used as a prognostic biomarker and as a tool for the early detection of various tumours.

Download Full-text

Meta-analysis of the prognostic value of long non-coding RNA PVT1 for cancer patients

Medicine ◽

10.1097/md.0000000000013548 ◽

2018 ◽

Vol 97 (49) ◽

pp. e13548 ◽

Cited By ~ 2

Author(s):

Chao Ma ◽

Xing-Guo Nie ◽

Yan-Li Wang ◽

Da-Peng Wu ◽

Qiu-dong Liang

Keyword(s):

Cancer Patients ◽

Prognostic Value ◽

Meta Analysis ◽

Non Coding Rna ◽

Long Non Coding Rna

Download Full-text

The clinicopathological and prognostic value of long non-coding RNA ZEB1-AS1 in solid tumors: A meta-analysis

Clinica Chimica Acta ◽

10.1016/j.cca.2018.05.011 ◽

2018 ◽

Vol 484 ◽

pp. 91-98 ◽

Cited By ~ 3

Author(s):

Chaojie Liang ◽

Jing Liu ◽

Hua Ge ◽

Yingchen Xu ◽

Guangming Li ◽

...

Keyword(s):

Solid Tumors ◽

Prognostic Value ◽

Meta Analysis ◽

Non Coding Rna ◽

Long Non Coding Rna

Download Full-text

LncRNA BLACAT1 May Serve as a Prognostic Predictor in Cancer: Evidence from a Meta-Analysis

BioMed Research International ◽

10.1155/2019/1275491 ◽

2019 ◽

Vol 2019 ◽

pp. 1-10 ◽

Cited By ~ 10

Author(s):

Hongyan Lu ◽

Haoran Liu ◽

Xiaoqi Yang ◽

Tao Ye ◽

Peng Lv ◽

...

Keyword(s):

Lymph Node ◽

Lymph Node Metastasis ◽

Meta Analysis ◽

Tumor Grade ◽

Tnm Stage ◽

Cancer Prognosis ◽

Node Metastasis ◽

Primary Endpoints ◽

The Relationship ◽

Review Manager

Background. As a newly discovered lncRNA, bladder cancer-associated transcript 1 (BLACAT1) has been reported to correlate with poor clinical outcomes in several different cancers. This study aimed to evaluate its generalized predictive value for cancer prognosis. Materials and Methods. We thoroughly searched PubMed, Embase, and Web of Science databases for eligible studies published until November 11, 2018, in which the relationship between BLACAT1 expression and cancer prognosis was explored. The analyses were performed using Review Manager Version 5.3 and Stata SE 12.0. The primary endpoints included overall survival (OS), pathological characteristics (TNM stage and tumor grade), lymph node metastasis (LNM), and distant metastasis. Results. Ten studies containing 861 patients with 7 different cancerous diseases were eventually included. The results demonstrated that patients with high lncRNA BLACAT1 expression had a significantly shorter OS (HR: 1.82, 95% CI: 1.44-2.30, p < 0.00001) than patients with low lncRNA BLACAT1 expression. Moreover, elevated BLACAT1 expression was significantly associated with advanced TNM stage (OR: 2.29, 95% CI: 1.15-4.56, p = 0.005), high tumor grade (OR: 1.67, 95% CI: 1.11-2.53, p = 0.01), and lymph node metastasis (OR: 2.53, 95% CI: 1.80-3.57, p < 0.00001). Meanwhile, the expression of BLACAT1 had no significant association with age (p = 0.92), gender (p = 0.55), and smoking (p = 0.62). Conclusion. High expression of lncRNA BLACAT1 may predict a poor prognosis in OS, TNM stage, tumor grade, and LNM. Its predictive roles were not significantly affected by age, gender, or smoking. Therefore, lncRNA BLACAT1 may serve as a promising predictor in cancer prognosis.

Download Full-text